These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
|Articles|December 8, 2011
Dr. Noel G. Boyle Discusses Pros and Cons of Warfarin
Advertisement
Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, also serves as Director of the Cardiac EP Labs at the David Geffen School of Medicine at UCLA. In this segment, he discusses the importance of stroke prevention in the management of atrial fibrillation, and the pros and cons of warfarin.
In addition, Dr. Boyles talks about patients' poor adherence to warfarin due to frequent monitoring, the need for simple and effective treatment solutions for atrial fibrillation, as well as the large amount of strokes attributed to atrial fibrillation.
Advertisement
Related to this article
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
5